Nurix FY2023 revenue $77.0M, net loss $143.9M; NX-5948 Fast Track, NX-2127 partial hold

Nurix Therapeutics, Inc.

FY2023 revenue $77.0M (up from $38.6M), net loss $143.9M ($2.65/share) vs $180.4M ($3.71) prior year.
Cash and investments $295.3M as of Nov 30, 2023, up from $268.7M at Aug 31, 2023.
NX-5948 granted FDA Fast Track for CLL; positive Phase 1 data with durable responses.
NX-2127 placed on partial clinical hold by FDA; expects to resolve in 2024.
Generated $100M non-dilutive capital from partners in 2023; licensed IRAK-4 degrader NX-0479/GS-6791 to Gilead.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nurix Therapeutics, Inc. reported financial results for the fiscal quarter and fiscal year ended November 30, 2023.

Period: the fiscal quarter and fiscal year ended November 30, 2023
Result: reported results

Exact text from the filing

today reported financial results for the fiscal quarter and fiscal year ended November 30, 2023, and provided a corporate update.

View on SEC.gov

Browse all earnings releases →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-24-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.